In our previous study, we generated a protease-cleavable pro-anti-TNFα Ab (i.e. pro-Infliximab) and proved that the pro-Infliximab can not only selectively be activated by MMP protease at diseases region, provide equivalent therapeutic efficacy to Infliximab but also maintain mouse immunity against Listeria infection in the RA mice model, leading to a significantly higher survival rate (71%) than that of the Infliximab treatment group (0%)25. Here, TNF is linked to rheumatoid arthritis.